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There are many times in which stress plays 
an influential role in alcohol addiction, 
but it is most influential during the time 
of relapse, in which there are cycles of 
heightened anxiety, depressive mood, 
and negative affect (Logrip et al., 2011). 
Clinical studies have suggested that the 
most common reason for relapse is the 
ability for alcohol to relieve these negative 
mood symptoms experienced during 
withdrawal (Hershon, 1977; Cloninger, 
1987). The target of this study is the 
corticotropin-releasing factor (CRF) 
system, which is understood to play a 
central role in regulating the behavioral 
stress response within the body (Dunn 
& Barridge, 1990). It is our hope that by 
regulating the depression experienced, we 
can begin the foundation for  long-term 
strategies in the prevention of relapse 
following protracted abstinence. Urocortin 
3 (Ucn 3) is a highly selective CRF2 
receptor  agonist (Lewis et al., 2001), 
and studies have shown that Ucn 3 has 
the ability to reduce behaviors associated 
with depression in animal models (Tanaka 
& Telegdy, 2008). However, the ability 
of Ucn 3 to diminish depressive-like 
behaviors during protracted withdrawal 
has yet to be studied. 
In order to examine the effects of Ucn 
3 following protracted abstinence, male 
and female Wistar rats (n=24) were given 
a liquid diet consisting of a chocolate 
nutritional shake, vitamins, minerals, 
and 10% ethanol as their sole source 
of nutrition for 25 days. Those in the 
control group were given sugar as a caloric 
substitute for the ethanol and were fed 
the average amount of the liquid diet that 
the ethanol group consumed the previous 
day. The results showed that there were no 
statistical differences found between diet 
and the body weight or fluid intake for 
either male or female rats. This ensures that 
any potential behavioral differences cannot 
be attributed to nutritional deficiency 
or dehydration. The amount of ethanol 
consumed by the rats has been previously 
shown to produce blood ethanol levels 
of 150-225 mg/dl (Macey, 1996). One 
day after removal of the liquid diet, the 
rats were observed for physical signs of 
alcohol withdrawal. The results from this 
assessment showed that ethanol liquid diet 
fed rats had significantly higher withdrawal 
scores, confirming physical dependence to 
alcohol. After five weeks during which rats 
were left undisturbed with the exception of 
routine husbandry, the rats were examined 
in the forced swim test. The results 
from the test did not show a statistically 
significant interaction between diet, drug, 
and time spent immobile. However, 
post hoc analysis did show a trend of less 
time spent immobile when injected with 
Ucn 3 during ethanol withdrawal that 
approached statistical significance F(1,19) 
= 3.72 p = .07. Further studies would need 
to be conducted in order to confirm the 
hypothesis that Ucn 3 has the ability to 
alleviate depression experienced during 
withdrawal, but the trend shows that there 
is reason to be cautiously optimistic about 
the future pharmaceutical opportunity 
to help those going through long term 
withdrawal in their path to remaining 
abstinent. 
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